GH Research PLC (NASDAQ:GHRS) Short Interest Up 11.8% in December

GH Research PLC (NASDAQ:GHRS) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,280,000 shares, an increase of 11.8% from the December 15th total of 2,040,000 shares. Based on an average trading volume of 72,900 shares, the days-to-cover ratio is currently 31.3 days. Currently, 7.5% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

GHRS has been the topic of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of GH Research in a research report on Friday, January 10th. Canaccord Genuity Group cut their target price on GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, November 18th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. boosted its position in GH Research PLC (NASDAQ:GHRS) by 1.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,686,689 shares of the company’s stock after purchasing an additional 85,000 shares during the period. RA Capital Management L.P. owned approximately 12.85% of GH Research worth $44,734,000 as of its most recent SEC filing. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Trading Up 3.3 %

Shares of GHRS stock opened at $8.88 on Monday. GH Research has a 1 year low of $5.50 and a 1 year high of $14.99. The stock has a fifty day moving average of $8.45 and a two-hundred day moving average of $9.05.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).